Do you want to read an article? Please log in or register.
Brief Report: Phase II Clinical Trial of Atezolizumab in Advanced Nonsmall Cell Lung Cancer Patients Previously Treated With PD-1-Directed Therapy
Lung Cancer
Related content
RECOMMENDED
Lung Cancer
The PESGA Trial: A Prospective, Open-Label, Single-Arm, Phase II Study to Evaluate First Line Therapy for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Patients, Treated by Induction Carboplatin/Etoposide/Pembrolizumab Followed by Maintenance of Pembrolizumab/ Sacituzumab Govitecan
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Clin Lung Cancer
Roisman LC, Mann S, Basel A, Marei R, Krayim B, Kornev G, Asna N, Peled N
doi: 10.1016/j.cllc.2025.02.002
Lung Cancer
Anti-PD1 based precision induction therapy in unresectable stage III non-small cell lung cancer: a phase II umbrella clinical trial
Nat Commun
Yi C, Bian D, Wang J, Hu S, Sun L, Yan Y, Wang S, Shen Z, Yu H, Yang Y, Zhou Y, Liu X, Song N, Zhu Y, Zhao D, Jiang G, Duan L, He W, Xie D, Dai J, Zhang L, Zhang P
doi: 10.1038/s41467-025-57184-z
Lung Cancer
A Patient-Centric, Open-Label, Multicenter, Phase II Study of Lorlatinib Monotherapy in the First-Line Treatment of Patients With locally Advanced or Metastatic ALK-Positive Non-Small Cell Lung Cancer (CTONG2203)
Clin Lung Cancer
Lin JX, Zhou Q, Yan HH, Liu AW, Wu GW, Chu Q, Du YY, Cui JW, Cheng Y, Yang Y, Xu HP, Tu HY, Wu YL, Liu SM
doi: 10.1016/j.cllc.2025.05.014
Lung Cancer
The Italian Mauris Phase IIIb Trial of Atezolizumab Plus Carboplatin and Etoposide for Patients With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer: 3-Year End-of-Study Results
Clin Lung Cancer
Morgillo F, Del Signore E, Bria E, de Marinis F, Ciardiello F, Garassino MC, Stefani A, Verderame F, Morabito A, Sbrana A, Tonini G, Gilli M, Berardi R, Taveggia PA, Bearz A, Delmonte A, Migliorino MR, Gridelli C, Fadda GM, Iero M, Ardizzoni A
doi: 10.1016/j.cllc.2025.07.003
Lung Cancer
Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study
Lancet Respir Med
Shi Y, Guo Y, Li X, Wu L, Chen Z, Yang S, Bi M, Zhao Y, Yao W, Yu H, Wang K, Zhao W, Sun M, Zhang L, He Z, Lin Y, Shi J, Zhu B, Wang L, Pan Y, Shi H, Sun S, Wen M, Zhou R, Guo S, Han Z, Yi T, Zhang H, Cang S, Yu Z, Zhong D, Cui J, Fang J, Gao J, Li M, Ma R, Jiang M, Qin J, Shu Y, Ye F, Hu S, Li W, Lu H, Yang M, Yi S, Zhang Y, Fan Y, Ji H, Liu Z, Wang H, Zhou X, Zhang D, Peng J, Shen H, Gao F, Wang T, Zhou A
doi: 10.1016/S2213-2600(24)00417-X
RECOMMENDED
Lung Cancer
An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04-2016
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Gelsomino F, Boni L, Tiseo M, Ricciardi S, Rocco D, Cortinovis DL, Proietto M, Cogoni A, Pasello G, Camerini A, Sperandi F, Colantonio I, Metro G, Mazzoni F, Baldini E, Veccia A, Bennicelli E, Cecilia Bettini A, Tognetto M, Ardizzoni A
doi: 10.1016/j.lungcan.2024.108059
Lung Cancer
Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase Inhibitors
Clin Lung Cancer
Bodor JN, Dowell J, Treat J, Subramanian J, Abdulla N, Lee E, Sankhala K, Lee CH, Makimoto G, Miyauchi E, Konduri K, Asahina H, Murakami S, Wen YF, Luo YH, Chang SY, Ewesuedo R, Zhou J, Goto Y
doi: 10.1016/j.cllc.2025.05.013
Lung Cancer
Chemotherapy Plus Anti-PD-1 or Anti-PD-L1 in Advanced PD-L1-Negative Squamous Cell Lung Carcinoma: A Systematic Review and Meta-Analysis
Clin Lung Cancer
Peruzzo N, Lenz G, Akhiwu T, Bilalaga M, Gaddipati GN, Müller NLF, Zarpellon L, Venero F, Corassa M, Cardona AF, Reuss JE, Pellini B
doi: 10.1016/j.cllc.2025.04.006
Lung Cancer
The impact of lung surgery, with or without (neo-)adjuvant therapy, on physical functioning in patients with nonsmall cell lung cancer: a scoping review
Eur Respir Rev
Haesevoets S, Arents E, Cops D, Quadflieg K, Criel M, Ruttens D, Daenen M, Stevens D, Surmont V, Demeyer H, Burtin C
doi: 10.1183/16000617.0156-2024